Liglinra

Linagliptin, the active ingredient in Liglinra, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It helps control blood glucose levels in adults diagnosed with type 2 diabetes mellitus, improving glycemic management when used alongside diet and exercise.

GNH USA supplies Liglinra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across regulated markets. The company adheres to EU GMP standards and provides comprehensive logistics support for timely delivery.

Liglinra (linagliptin) is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance. - Type 2 diabetes mellitus (monotherapy): Improves fasting and post‑prandial glucose levels when used alone. - Type 2 diabetes mellitus (combination with metformin): Provides additional HbA1c reduction beyond metformin alone. - Type 2 diabetes mellitus (combination with insulin): Enhances glycemic control while allowing possible insulin dose reduction.

Linagliptin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Nasopharyngitis: mild upper respiratory inflammation. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, diarrhea, or abdominal discomfort. - Upper respiratory infection: symptoms of cold or flu. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or hepatitis. - Bullous pemphigoid: autoimmune skin blistering disorder. - Severe joint pain: arthralgia that may indicate underlying inflammation.

When prescribing linagliptin, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required; monitor renal function regularly. - Hepatic impairment: use with caution; periodic liver enzyme testing is advised. - Hypersensitivity: discontinue immediately if rash, angioedema, or other allergic signs appear. - Pancreatitis risk: advise patients to report persistent or severe abdominal pain. - Cardiovascular disease: no dose change needed, but monitor for any new cardiac symptoms. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Linagliptin can interact with other medicines, necessitating vigilance.

Major Interactions (Avoid): - Strong P‑gp inhibitors (e.g., itraconazole, verapamil): may increase linagliptin exposure. - Concomitant use with insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Metformin: monitor renal function and lactic acidosis risk. - Sulfonylureas: adjust dose to avoid low blood sugar. - Rifampin: may reduce linagliptin efficacy; consider alternative therapy.